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Received March 21, 2013; accepted May 23, 2013AbstractBackground: Ovarian adult-type granulosa cell tumors (GCTs) are characterized as low-malignant and late-recurrent ovarian tumors. Although
some clinical and pathological prognostic factors have been reported, other factors have yet to be sufficiently investigated for necessary
confirmation. The aim of this study was to test the correlation between clinical factors and outcome, based on patients seen in a single institute.
Methods: Thirty patients with pathologically confirmed adult-type GCTs between 1984 and 2010 were reviewed retrospectively. Among them,
eight (26.7%) had recurrence, which subsequently contributed to two mortalities.
Results: In a comparison of the clinical characteristics of the premenopausal and postmenopausal women with GCT, all of the postmenopausal
women had symptoms (100% vs. 63.6%, p ¼ 0.01). With regard to disease recurrence, only abnormal preoperative serum cancer antigen 125
level (35 U/mL) was significant (50% vs. 11%, p ¼ 0.03), and residual tumor showed a borderline trend (100% vs. 21.4%, p ¼ 0.06). Other
factors, including International Federation of Gynecology and Obstetrics stage, tumor size, tumor rupture prior to or during operation, body mass
index, parity, serum estrogen level, and adjuvant therapy, were not statistically significant.
Conclusion: Physicians should be alert to the difference in the symptom presentation of GCTs between pre- and postmenopausal women, giving
particular attention to the usefulness of the preoperative serum level of cancer antigen 125 in patients with GCTs. More evidence is needed to
confirm this observation.
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Table 1
Characteristics of the 30 patients with granulosa cell tumors of the ovary.
All patients
(n ¼ 30)
Premenopausal
(n ¼ 19)
Postmenopausal
(n ¼ 11)
p
Symptoms 0.039
No symptom 4 (13.3) 0 (0) 4 (36.4)
Bleeding disorder 9 (30) 7 (36.8) 2 (18.2)
Abdominal pain/
distension
12 (40) 8 (42.1) 4 (36.4)
Palpable mass 5 (16.7) 4 (21.1) 1 (9.1)
Symptoms 0.012
No 4 (13.3) 0 (0) 4 (36.4)
Yes 26 (86.7) 19 (100) 7 (63.6)
Operation 0.806
USO 9 (30) 5 (26.3) 4 (36.4)
TH þ BSO 8 (26.7) 5 (26.3) 3 (27.3)
Complete staging
surgery
13 (43.3) 9 (47.4) 4 (36.4)
Tumor rupture 0.104
No 22 (73.3) 16 (84.2) 6 (54.5)
Yes 8 (26.7) 3 (15.8) 5 (45.5)
FIGO stage 0.110
IA 22 (73.3) 16 (84.2) 6 (54.5)
IC 5 (16.7) 3 (15.8) 2 (18.2)
II 0 0 0
III 2 (6.7) 0 2 (18.2)
IV 1 (3.3) 0 1 (9.1)
CA125 IU/mL 0.266
<35 18 (60) 13 (68.4) 5 (45.5)
35 12 (40) 6 (31.6) 6 (54.5)
Body mass index
kg/m2
1.000
<25 17 (56.7) 11 (57.9) 6 (54.5)
25 13 (43.3) 8 (42.1) 5 (45.5)
Adjuvant treatment 0.104
No 22 (73.3) 16 (84.2) 6 (54.5)
Chemotherapy 8 (26.7) 3 (15.8) 5 (45.5)
Residual tumor
after treatment
0.126
Absence 28 (93.3) 19 (100) 9 (81.8)
Presence 2 (6.7) 0 2 (18.2)
Data are presented as n (%).
BSO ¼ bilateral salpingo-oophorectomy; CA125 ¼ preoperative serum level
of cancer antigen 125; complete staging surgery ¼ washing cytology, TH,
BSO, omentectomy, pelvic and para-aortic lymphadenectomy, and multiple
randomized biopsies; TH ¼ total hysterectomy; USO ¼ unilateral salpingo-
oophorectomy.
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Adult-type granulosa cell tumors (GCTs) of the ovary ac-
count for 1e2% of all ovarian tumors, and are derived from
ovarian sex-cord stromal hormone-secreting tumors.1 GCTs
are characterized as low-malignant and late-recurrent ovarian
tumors,2 but it is evident that patients with this illness have
recurrent disease, which typically is the eventual cause of
death.3 Although most symptoms are nonspecific, the clinical
symptoms of GCTs may include abdominal pain or distention,
and abnormal bleeding or palpable pelvic mass.4 Due to the
rarity of GCTs, the prognostic factors of tumor recurrence are
uncertain, although some clinical or pathological factors, such
as advanced stage (Stage IIeIV), large tumor size, high
mitotic index, tumor rupture, and the presence of residual
tumor after initial surgery have been reported.2,3 The potential
conventional tumor marker of GCTs is inhibin,5 although it is
used for follow-up. Because the serum level of cancer antigen
125 (CA125) might be elevated in advanced stage and tumor
rupture, in theory, and advanced stage and tumor rupture are
reported to be correlated with tumor recurrence, it is rational
to suppose that the preoperative serum level of CA125 might
also contribute to recurrence. The aim of this study was to test
the correlation between clinical factors and outcome.
2. Methods
Thirty patients with pathologically confirmed GCTs be-
tween 1984 and 2010 at Taipei Veterans General Hospital were
reviewed retrospectively. Approval for the study was obtained
from the local ethics committee (VGHIRB 98-11-02). The
characteristics assessed included age, gravidity, body mass
index (BMI), menopausal status, preoperative serum levels of
CA125 and estrogen, tumor size, tumor rupture prior to or
during operation, surgical method, pathological finding, In-
ternational Federation of Gynecology and Obstetrics (FIGO)
stage, and adjuvant therapy. Survival probabilities were plotted
using the KaplaneMeier life table, and survival differences
were tested for significance using the log-rank test. Statistical
analysis was conducted using SPSS version 18 (SPSS Inc.,
Chicago, IL, USA), including Chi-square tests and Fisher’s
exact test. A p value < 0.05 was defined as statistically sig-
nificant and all tests were two-tailed.
3. Results
GCTs occurred in the premenopausal status of 19 of the 30
patients. Clinical factors, with the exception of clinical
symptoms, of both menopausal and postmenopausal status
were similar without a statistically significant difference
(Table 1). All premenopausal women had symptoms, but
nearly 40% of postmenopausal women were asymptomatic
( p ¼ 0.012). Abdominal pain or distention (40%, n ¼ 12) was
most common, followed by bleeding disorder (30%, n ¼ 9).
Four patients were asymptomatic and the GCT was found
accidentally, and all were postmenopausal. The mean age at
diagnosis was 48.7 years (range, 32e77 years), and the meanfollow-up period was 101.8 months (range, 26e316 months).
Mean size of the GCTs was 10.4 cm (range, 5e20 cm).
Seventeen of the 30 patients underwent an incomplete surgery
(56.7%). The majority of the patients were Stage IA (73.3%,
n ¼ 22; Table 1). Eight patients (26.7%) underwent adjuvant
therapy, and all were treated with multiagent chemotherapy
with bleomycin, etoposide, and cisplatin (Table 1).
There were eight cases of recurrence (26.7%) during the
follow-up period (Table 2). Recurrence was associated with
elevated preoperative serum levels of CA125 (35 IU/mL), to
a statistically significant degree (50% vs. 11%, p ¼ 0.03).
Other factors, including FIGO stage, tumor size, tumor rupture
prior to or during operation, body mass index, parity, serum
estrogen level, complete staging surgery, or adjuvant therapy
were not statistically significantly associated with disease
Table 2
Prognostic factors of the 30 patients with granulosa cell tumors of the ovary.
Total patients
n ¼ 30
Recurrence
n ¼ 8
No recurrence
n ¼ 22
p
FIGO stage 0.166
I 27 6 21
IIeIV 3 2 1
Body mass index 0.242
<25 17 3 14
25 13 5 8
Parity 1.000
Nullipara 7 2 5
Multipara 23 6 17
CA125 (IU/mL)a 0.034
<35 18 2 16
35 12 6 6
Estrogen (mU/mL)b 0.338
<60 8 1 7
60 11 4 7
Estrogen (mU/mL)c 0.545
<35 6 1 5
35 5 2 3
Size of tumor 1.000
<10 cm 13 3 10
10 cm 17 5 12
Tumor ruptured 0.158
Yes 8 4 4
No 22 4 18
Complete surgery 0.698
Yes 13 4 9
No 17 4 13
Residual tumor 0.064
Yes 2 2 0
No 28 6 22
Adjuvant therapy 0.158
Yes 8 4 4
No 22 4 18
FIGO ¼ International Federation of Gynecology and Obstetrics.
a Preoperative serum cancer antigen 125 level.
b Preoperative serum estrogen level of premenopausal women.
c Preoperative serum estrogen level of postmenopausal women.
d Rupture of tumor prior to and during operation.
Table 4
Analysis of the patients with granulosa cell tumors who died of disease.
Total patients
(n ¼ 30)
Alive
(n ¼ 28)
Deceased
(n ¼ 2)
p
FIGO stage 0.193
I 27 26 1
IIeIV 3 2 1
Body mass index 1.000
<25 17 16 1
25 13 12 1
Parity 1.000
Nullipara 7 7 0
Multipara 23 21 2
CA125 (IU/mL)a 0.152
<35 18 18 0
35 12 10 2
Estrogen (mU/mL)b 1.000
<60 8 8 0
60 11 10 1
Estrogen (mU/mL)c 1.000
<35 6 5 1
35 5 5 0
Size of tumor 0.492
<10 cm 13 13 0
10 cm 17 15 2
Tumor ruptured 0.469
Yes 8 7 1
No 22 21 1
Complete surgery 1.000
Yes 13 12 1
No 17 16 1
Residual tumor 0.131
Yes 2 1 1
No 28 27 1
Adjuvant therapy 0.469
Yes 8 7 1
No 22 21 1
FIGO ¼ International Federation of Gynecology and Obstetrics.
a Preoperative serum cancer antigen 125 level.
b Preoperative serum estrogen level of premenopausal women.
c Preoperative serum estrogen level of postmenopausal women.
d Rupture prior to and during operation.
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mary surgery showed a marginal association ( p ¼ 0.06).
The median time to recurrence was 83 months (range,
13e227 months), based on the imaging findings. Two patientsTable 3
Clinical findings of patients who had recurrent disease.
Case Age
(y)
Stage Primary treatment Residual
tumor
Pretreatment
CA125 (U/mL)
1 32 IA USO No 42
2 56 IV USO þ C/Ta Yes 65
3 35 IA USO No 11
4 41 IA TH þ BSO No 12
5 73 IIIC Staging surgery þ C/Ta Yes 82.4
6 48 IC Staging surgery þ C/Ta No 56
7 44 IC Staging surgery þ C/Ta No 76.3
8 38 IA Staging surgery No 37
C/T ¼ chemotherapy; DFS ¼ disease-free survival; PC ¼ peritoneal cavity; TH ¼
hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenec
oophorectomy.
a Multi-agent chemotherapy with bleomycin, etoposide, and cisplatin.
b Alive status with presence of a tumor.underwent repeat surgical excision with pathological confir-
mation. Peritoneal recurrence was most common (75%, n¼ 6),
and two cases had recurrence in the liver parenchyma. All pa-
tients with recurrent GCTwere treated with chemotherapy withDFS
(mo)
Site of recurrence Treatment for
recurrence
Outcome Follow-up after
recurrence (mo)
134 Liver parenchyma Surgery þ C/T Alive 206
96 PC C/T Die 131
83 PC Surgery þ C/T Alive 49
227 PC C/T Alive 70
13 PC C/T Aliveb 6
58 PC C/T Alive 90
99 Liver parenchyma C/T Die 28
46 PC C/T Alive 12
total hysterectomy; staging surgery ¼ complete staging surgery included total
tomy, omentectomy, and multiple random biopsies; USO ¼ unilateral salpingo-
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cisplatin-based or paclitaxel-based chemotherapy (Table 3).
Two patients finally died of the disease (Table 4). However, no
single prognostic factor could predict the survival of the pa-
tients, whether recurrent patients (n¼ 8) or all patients (Table 4,
n ¼ 30). The 5-year and 10-year survival rates for all stages
were 96.7%. Multivariate analysis did not show significance
due to the small case number; however, based on univariate
analysis, we found that low preoperative serum CA125
(<35 IU/mL) might benefit in survival, because recurrence rate
was low in this group (Table 2).
4. Discussion
Ovarian adult-type GCTs account for 1e2% of all ovarian
tumors, and present distinct hormonal behaviors and low-grade
malignancies compared with common types of ovarian epithelial
tumors. Ovarian adult-type GCTs commonly occur in the peri-
menopausal or early postmenopausal female; the median age at
diagnosis was reported to be 46e54 years,1e5 which was also
supported by our current study. Ovarian CGTs are frequently
functional, often with estrogen-secreting characteristics; there-
fore it is rational to suppose that bleeding disorder may be the
most common symptom, especially for postmenopausal
women.6 This hypothesis has been supported in the literature.7e9
For example, Auranen et al7 reported that 27 of 35 patients had
bleeding disorder, Chua et al8 showed 40% of patients had GCT
associated with endometrial hyperplasia, and Ohel et al9 re-
ported 6.4% and 11% of 172 patients were associated with
breast cancer and endometrial cancers, respectively. All these
studies confirmed the relationship between an excess of estrogen
and ovarian GCT. However, 36% (4/11) of postmenopausal
women with GCT in the current study were asymptomatic,
which could easily be explained by the low serum levels of
estrogen in nearly half of the postmenopausal patients (Table 2).
A previous report mentioned that postmenopausal bleeding is a
common presenting sign,1 and that fewer than one-fifth of
postmenopausal women had postmenopausal bleeding; howev-
er, one-third of the patients had irregular menstruation (Table 1).
We did not find endometrial lesions in the current study. By
contrast, nonspecific abdominal symptoms, including pain,
distension, and mass, were most common and in nearly 60%
(17/30) of all patients, which was related to the fact that GCTs
are oftentimes large (>10e15 cm) and tend to hemorrhage.2 In
addition, many women have a palpable or pelvic mass2; one-
fifth of patients in this study also described this symptom.
Most studies report that the leading prognostic factors of
GCTs were clinical and pathological parameters. The common
clinical parameters include FIGO stage of the disease, tumor
size (>10e15 cm), tumor rupture prior to or during operation,
age at diagnosis, presence or absence of residual tumor after
initial surgery, or even complete surgical staging without
lymphadenectomy or postoperative adjuvant chemotherapy
with a bleomycin, etoposide, and cisplatin regimen.2,3,7e12
Common pathological parameters include nuclear atypia,
mitotic index (mitotic index  4e10 mitoses/10 high-power
fields), and some histopathological or serum markers.1,13e15Because the majority of patients (n ¼ 27) in this study were
supposed Stage I, and the sample size was small (n ¼ 30), the
correlation between stage and recurrence seemed to be sta-
tistically insignificant, although the majority of studies show
that the initial stage of GCT is the most important prognostic
factor.1e3 Preoperative serum parameters, including inhibin B,
transforming growth factor family secreted by granulosa cells,
and anti-Mullerian hormone and estradiol secreted by gran-
ulosa cells are also reported to be valuable.2,16,17 However, we
cannot comment on this issue, because we did not detect these
parameters in the patients studied, although the preoperative
serum levels of estrogen seemed not to be correlated with
prognosis in the current study. By contrast, preoperative serum
levels of CA125, which were conventionally considered an
important prognostic factor for epithelial ovarian tumor,18,19
seemed to be statistically significant to tumor recurrence. If
the patients had a preoperative serum level of CA125  35 IU/
mL, half of them were recurrent; this compares with 10% of
patients who had a preoperative serum level of CA125 <
35 IU/mL. This finding may be related to the vascular nature
of GCT and the tendency to hemorrhage, and the peritoneal
irritation might have contributed to the elevated serum level of
CA125.20,21 In addition, the presence of peritoneal irritation
might hint at the possibility of tumor dissemination preoper-
atively, which is correlated with advanced stage, bigger tu-
mors, tumor rupture, and a high possibility of residual tumor
after primary surgery.
Complete staging surgery is emphasized in some published
reports,10,12 although the role of lymphadenectomy is highly
controversial and the majority of published papers did not
support the routine use of lymphadenectomy during complete
staging surgery, based on the extremely low incidence of
lymph node metastases in patients with GCT.10,22e24 In this
study, complete staging surgery seemed to be statistically
insignificant, even for he Stage I patients. In the Taiwanese
Gynecologic Oncology Group (TJOG) study, the 176 patients
with GCT after primary surgical treatment also showed that
complete staging surgery seemed to be insignificant.3 By
contrast, complete excision of the tumor seemed to be a more
apparent prognostic factor in the TJOG study.3 In a previous
Korean study, residual tumor was also reported as the only
significant factor of recurrence in multivariate analysis.12 In
this study, we also found that residual tumor after primary
surgery might be important for prognosis, although without
statistical significance. The possible explanation is the small
size of the study population.
In this study, we only evaluated the correlation between the
clinico-pathological factors and prognosis of adult-type GCTs,
and failed to test the role of gene mutation or alteration of
GCTs, such as the FOXL2 gene [c.402C > G (C134W)].25e27
This gene is now considered pathognomonic of GCTs, con-
firming a diagnosis of adult-type GCTs.26 FOXL2 is a fork-
headewinged helix transcription factor that is an evolutionarily
conserved single-exon gene of 2.7 kb located at 3q23 that en-
codes for a 376 amino-acid protein belonging to the large family
of forkhead transcription factors.26 In addition, the prognostic
significance of FOXL2 mutations and mRNA expression has
25B.-S. Huang et al. / Journal of the Chinese Medical Association 77 (2014) 21e25also been reported in adult GCTs of the ovary by D’Angelo’s
group,28 because the authors found that higher FOXL2 protein
expression had worse overall survival and disease-free survival
than those with negative or weakly immunoreactive tumors.
In conclusion, we found that some of the postmenopausal
women with GCTs were diagnosed by routine physical ex-
amination in the current study. We also emphasized the
possible value of an elevated preoperative serum CA125 level
in these women with GCTs, because elevated preoperative
serum levels of CA125 could predict future recurrence in
patients with GCTs. More evidence is needed to confirm this
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